Response to targeted therapy in urachal adenocarcinoma

Isabella Testa, Elena Verzoni, Paolo Grassi, Maurizio Colecchia, Filomena Panzone, Giuseppe Procopio

Research output: Contribution to journalArticlepeer-review


We report the case of a young woman diagnosed with metastatic urachal carcinoma. A multimodal approach was used for the management of this patient. Due to disease progression despite surgery and two different chemotherapy regimens (neoadjuvant capecitabine + irinotecan + oxaliplatin and docetaxel + cisplatin after surgery), treatment with sunitinib was eventually started. Treatment with sunitinib resulted in stable disease and improvement of symptoms. Sunitinib was discontinued due to the occurrence of metrorrhagia, and restarted one week later. Disease eventually progressed and the patient died 18 months after the onset of symptoms. This is the first report on the use of sunitinib for the management of urachal carcinoma and provides initial evidence supporting the use of targeted therapy in this setting.

Original languageEnglish
Article number5529
Pages (from-to)124-127
Number of pages4
JournalRare Tumors
Issue number4
Publication statusPublished - Aug 20 2014


  • Sunitinib
  • Targeted therapies
  • Urachal adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Histology


Dive into the research topics of 'Response to targeted therapy in urachal adenocarcinoma'. Together they form a unique fingerprint.

Cite this